Machine learning of ECG waveforms and cardiac magnetic resonance for response and survival after cardiac resynchronization therapy.

Journal: Computers in biology and medicine
PMID:

Abstract

Cardiac resynchronization therapy (CRT) can lead to marked symptom reduction and improved survival in selected patients with heart failure with reduced ejection fraction (HFrEF); however, many candidates for CRT based on clinical guidelines do not have a favorable response. A better way to identify patients expected to benefit from CRT that applies machine learning to accessible and cost-effective diagnostic tools such as the 12-lead electrocardiogram (ECG) could have a major impact on clinical care in HFrEF by helping providers personalize treatment strategies and avoid delays in initiation of other potentially beneficial treatments. This study addresses this need by demonstrating that a novel approach to ECG waveform analysis using functional principal component decomposition (FPCD) performs better than measures that require manual ECG analysis with the human eye and also at least as well as a previously validated but more expensive approach based on cardiac magnetic resonance (CMR). Analyses are based on five-fold cross validation of areas under the curve (AUCs) for CRT response and survival time after the CRT implant using Cox proportional hazards regression with stratification of groups using a Gaussian mixture model approach. Furthermore, FPCD and CMR predictors are shown to be independent, which demonstrates that the FPCD electrical findings and the CMR mechanical findings together provide a synergistic model for response and survival after CRT. In summary, this study provides a highly effective approach to prognostication after CRT in HFrEF using an accessible and inexpensive diagnostic test with a major expected impact on personalization of therapies.

Authors

  • Derek J Bivona
    Department of Medicine, University of Virginia Health System, Charlottesville, VA 22903, USA; Department of Biomedical Engineering, University of Virginia, Charlottesville, VA 22903, USA.
  • Sona Ghadimi
    Department of Biomedical Engineering, University of Virginia, Health System, Box 800759, Charlottesville, VA, 22908, USA.
  • Yu Wang
    Clinical and Technical Support, Philips Healthcare, Shanghai, China.
  • Pim J A Oomen
    Department of Biomedical Engineering, University of California Irvine, Irvine, CA 92697, USA.
  • Rohit Malhotra
    Department of Medicine, University of Virginia Health System, Charlottesville, VA 22903, USA.
  • Andrew Darby
    Department of Medicine, University of Virginia Health System, Charlottesville, VA 22903, USA.
  • J Michael Mangrum
    Department of Medicine, University of Virginia Health System, Charlottesville, VA 22903, USA.
  • Pamela K Mason
    Department of Medicine, University of Virginia Health System, Charlottesville, VA 22903, USA.
  • Sula Mazimba
    Department of Cardiovascular Medicine, University of Virginia, Charlottesville, VA; Transplant Institute, AdventHealth, Orlando, FL.
  • Amit R Patel
    Cardiac Imaging Center, University of Chicago Medical Center, Chicago, Illinois.
  • Frederick H Epstein
    Department of Biomedical Engineering, University of Virginia, Health System, Box 800759, Charlottesville, VA, 22908, USA. fhe6b@virginia.edu.
  • Kenneth C Bilchick
    Department of Medicine, University of Virginia Health System, Charlottesville, VA, USA.